In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease

被引:510
作者
Contrino, J
Hair, G
Kreutzer, DL
Rickles, FR
机构
[1] CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS MSD02,ATLANTA,GA 30333
[2] UNIV CONNECTICUT,SCH MED,DEPT MED,FARMINGTON,CT 06032
[3] UNIV CONNECTICUT,SCH MED,DEPT SURG,FARMINGTON,CT 06032
[4] UNIV CONNECTICUT,SCH MED,DEPT PATHOL,FARMINGTON,CT 06032
[5] EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322
[6] VET ADM MED CTR,NEWINGTON,CT 06111
关键词
D O I
10.1038/nm0296-209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of tissue factor (TF) in the endothelium has been observed only rarely in human disease and has been thought to be elaborated on the surface of vascular endothelial cells (VECs) in vitro as an artifact of tissue culture. Using monoclonal antibodies and a novel probe for functional TF, we have localized TF to the VECs (and tumor cells) within the tumors of seven patients with invasive breast cancer but not in the VECs (or tumor cells) of benign tumors from ten patients with fibrocystic disease of the breast. The potent procoagulant TF was shown to be a marker of the initiation of angiogenesis in human breast cancer. Further evidence that the TF was the demonstration of a similar distribution of cross-linked fibrin only in the VECs of the malignant tumors. We interpret these data as further support for the concept that tumor cells can activate nearby VECs and regulate blood vessel growth in vivo. Large clinical-pathologic studies will be necessary to determine whether TF is a useful marker for the ''switch to the angiogenic phenotype'' in human breast disease and/or correlates with the thromboembolic complications of breast cancer.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 53 条
  • [31] MAYNARD JR, 1977, BLOOD, V50, P387
  • [32] MCKEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80
  • [33] MIYAUCHI S, 1988, IN VITRO CELL DEV B, V24, P753
  • [34] MONOCLONAL-ANTIBODY ANALYSIS OF PURIFIED AND CELL-ASSOCIATED TISSUE FACTOR
    MORRISSEY, JH
    FAIR, DS
    EDGINGTON, TS
    [J]. THROMBOSIS RESEARCH, 1988, 52 (03) : 247 - 261
  • [35] C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER
    MUSS, HB
    THOR, AD
    BERRY, DA
    KUTE, T
    LIU, ET
    KOERNER, F
    CIRRINCIONE, CT
    BUDMAN, DR
    WOOD, WC
    BARCOS, M
    HENDERSON, IC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (18) : 1260 - 1266
  • [36] NEMERSON Y, 1988, BLOOD, V71, P1
  • [37] IDENTIFICATION AND PARTIAL-PURIFICATION OF A NOVEL TUMOR-DERIVED PROTEIN THAT INDUCES TISSUE FACTOR ON CULTURED HUMAN-ENDOTHELIAL CELLS
    NOGUCHI, M
    SAKAI, T
    KISIEL, W
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 160 (01) : 222 - 227
  • [38] ANTIMETASTATIC AGENTS .2. SUMMARY OF THE INTERACTIONS OF TUMOR-CELLS WITH BLOOD-COAGULATION FACTORS, PLATELETS, FIBRINOLYTIC FACTORS, AND INFLAMMATORY CELLS AND THEIR SOLUBLE MEDIATORS - POTENTIAL FOR THERAPEUTIC INTERVENTIONS
    RICKLES, FR
    HANCOCK, WW
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1988, 14 (01) : 126 - 132
  • [39] HEMOSTATIC ALTERATIONS IN CANCER-PATIENTS
    RICKLES, FR
    LEVINE, M
    EDWARDS, RL
    [J]. CANCER AND METASTASIS REVIEWS, 1992, 11 (3-4) : 237 - 248
  • [40] RICKLES FR, 1994, HEMOSTASIS THROMBOSI, P1164